Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298495 | 1.00 | TAAR1 (0.41) | TAAR1SLC1A1MEN1KMT2AFFAR1 | |
| SCHEMBL6692381 | 1.00 | TAAR1 (0.41) | TAAR1SLC1A1MEN1KMT2AFFAR1 | |
| SCHEMBL6303028 | 0.86 | SLC13A5 (0.35) | SLC13A5MAOBCYP2C19 | |
| SCHEMBL6692398 | 0.86 | SLC13A5 (0.35) | SLC13A5MAOBCYP2C19 | |
| SCHEMBL6303531 | 0.84 | SLC13A5 (0.51) | TAAR1MEN1KMT2AFFAR1SLC13A5 | |
| SCHEMBL6695081 | 0.84 | SLC13A5 (0.49) | MEN1KMT2AFFAR1SLC13A5CYP2D6 | |
| SCHEMBL6692391 | 0.84 | SLC13A5 (0.49) | MEN1KMT2AFFAR1SLC13A5CYP2D6 | |
| SCHEMBL6302904 | 0.84 | SLC13A5 (0.49) | MEN1KMT2AFFAR1SLC13A5CYP2D6 | |
| SCHEMBL6297597 | 0.83 | SLC13A5 (0.44) | MEN1KMT2AFFAR1SLC13A5CYP2D6 | |
| SCHEMBL6692548 | 0.83 | SLC13A5 (0.44) | MEN1KMT2AFFAR1SLC13A5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | TAAR1 4863/4885SLC1A1 3914/4885MEN1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.